Relationship between leptin and all-cause and cardiovascular mortality in chronic hemodialysis patients;Relación entre leptina y mortalidad global y cardiovascular en pacientes en hemodiálisis

Nefrologia

Volumn 31, Issue 2, 2011, Pages 206-212

  Diez J J ^a   Bossola, M ^b   Fernandez Reyes M J ^c   di Stasio, E ^b   Tazza, L ^b   Luciani, G ^b   Codoceo, R ^d   Iglesias, P ^a   Rodriguez A ^c   Gonzalez E ^d   Selgas, R ^d  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b CATHOLIC UNIVERSITY   (Italy)

^c HOSPITAL GENERAL DE SEGOVIA   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Cardiovascular disease; End stage renal disease; Hemodialysis; Leptin; Mortality

Indexed keywords

LEPTIN;

AGED; ARTICLE; BLOOD; BODY MASS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; FEMALE; FOLLOW UP; HUMAN; ITALY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NONPARAMETRIC TEST; OBESITY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RISK FACTOR; SPAIN; STATISTICS;

AGED; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; LEPTIN; MALE; MIDDLE AGED; MORTALITY; OBESITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; SPAIN; STATISTICS, NONPARAMETRIC;

EID: 79955083013     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.Dec.10629     Document Type: Article

References (26)

1. Rucker D, Tonelli M. Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol 2009;5:287-96.
2. Brunner FP, Selwood NH on behalf of the EDTA Registry Committee. Profile of patients on RRT in Europe and death rates due to major causes of death groups. Kidney Int 1992;42:S4-15.
3. Locatelli F, Manzoni C, Del Vecchio L, Di Filippo S. Changes in United States Renal Data System, 2006.
4. Herzog CA. Sudden cardiac death and acute myocardial infarction in dialysis patients: perspectives of a cardiologist. Semin Nephrol 2005;25:363-6.
5. Bodary PF, Gu S, Shen Y, Hasty AH, Buckler JM, Eitzman DT. Recombinant leptin promotes atherosclerosis and thrombosis in apolipo-protein E-deficient mice. Arterioscler Thromb Vasc Biol 2005;25:e119-22.
6. Nakamura Y, Ueshima H, Okuda N, Murakami Y, Miura K, Kita Y, et al. Relation of serum leptin to blood pressure of Japanese in Japan and Japanese-Americans in Hawaii. Hypertension 2009;54:1416-22.
7. Bullo M, García-Lorda P, Megias I, Salas-Salvadó J. Systemic inflammation, adipose tissue, tumor necrosis factor and leptin expression. Obes Res 2003;11:525-31.
8. Heimbürger O, Lönnqvist F, Danielsson A, Nordenström J, Stenvin-kel P. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997;8:1423-30.
9. Bossola M, Muscaritoli M, Valenza V, Panocchia N, Tazza L, Cascino A, et al. Anorexia and serum leptin levels in hemodialysis patients. Nephron Clin Pract 2004;97:c76-82.
10. Díez JJ, Iglesias P, Fernández-Reyes MJ, Aguilera A, Bajo MA, Álva-rez-Fidalgo P, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol 2005;62:242-9.
11. Scholze A, Rattensperger D, Zidek W, Tepel M. Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring) 2007;15:1617-22.
12. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
13. Eikelis N, Lambert G, Wiesner G, Kaye D, Schlaich M, Morris M, et al. Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function. Am J Physiol Endocrinol Metab 2004;286:E744-52.
14. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR, et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 2004;89:3872-8.
15. Singhal A, Farooqi IS, Cole TJ, O'Rahilly S, Fewtrell M, Kattenhorn M, et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation 2002;106:1919-24.
16. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001;104:3052-6.
17. Sattar N, Wannamethee G, Sarwar N, Chernova J, Lawlor DA, Kelly A, et al. Leptin and coronary heart disease. Prospective study and systematic review. J Am Coll Cardiol 2009;53:167-75.
18. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.
19. Abbott KC, Glanton CW, Trespalacios FC, Oliver DK, Ortiz MI, Agodoa LY, et al. Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int 2004;65:597-605.
20. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-9.
21. Fouque D, Vennegoor M, Ter Wee P, Wanner C, Basci A, Canaud B, et al. EBPG Guideline on nutrition. Nephrol Dial Transplant 2007;Suppl. 2:ii45-87.
22. Sundell J, Huupponen R, Raitakari OT, Nuutila P, Knuuti J. High serum leptin is associated with attenuated coronary vasoreactivity. Obes Res 2003;11: 776-82.
23. Vecchione S, Maffei A, Colella S, Aretini A, Poulet R, Frati G, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002;51:168-73.
24. Díez JJ, Estrada, Bajo MA, Fernández-Reyes MJ, Grande C, Del Peso G, et al. High stable serum adiponectin levels are associated with a better outcome in prevalent dialysis patients. Am J Nephrol 2009;30:244-52.
25. Iglesias P, Díez JJ, Fernández-Reyes MJ, Bajo MA, Aguilera A, Méndez J, et al. Effects of short-term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients. Nephrol Dial Transplant 2002;17:260-4.
26. Aquilera A, Bajo MA, Rebollo F, Díez JJ, Díaz C, Paiva A, et al. Leptin as a marker of nutrition and cardiovascular risk in peritoneal dialysis patients. Adv Perit Dial 2002;18:212-7.